A comparison of comorbidity indices and estimates of life expectancy for men with prostate cancer
DOI:
https://doi.org/10.2340/sju.v60.43810Keywords:
CCI, Comorbidities, Life expectancy, MDCI, Prostate cancerAbstract
N/A
Downloads
References
Ventimiglia E, Gedeborg R, Styrke J, et al. Radical treatment for prostate cancer in men with limited life expectancy in Sweden. JAMA Netw Open. 2025;8(5):e258572. https://doi.org/10.1001/jamanetworkopen.2025.8572 DOI: https://doi.org/10.1001/jamanetworkopen.2025.8572
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8 DOI: https://doi.org/10.1016/0021-9681(87)90171-8
Daskivich TJ, Kwan L, Dash A, et al. An age adjusted comorbidity index to predict long-term, other cause mortality in men with prostate cancer. J Urol. 2015;194(1):73–78. https://doi.org/10.1016/j.juro.2015.01.081 DOI: https://doi.org/10.1016/j.juro.2015.01.081
Gedeborg R, Sund M, Lambe M, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32(4):607–615. https://doi.org/10.1097/EDE.0000000000001358 DOI: https://doi.org/10.1097/EDE.0000000000001358
Westerberg M, Irenaeus S, Garmo H, et al. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study. PLoS One. 2024;19(1):e0296804. https://doi.org/10.1371/journal.pone.0296804 DOI: https://doi.org/10.1371/journal.pone.0296804
Westerberg M, Ahlberg M, Orrason AW, et al. Assessment of variability in life expectancy in older men by use of new comorbidity indices. A nationwide population-based study. Scand J Urol. 2024;59:207–209. https://doi.org/10.2340/sju.v59.42504 DOI: https://doi.org/10.2340/sju.v59.42504
Stranne J. 2023/2024 update of the national prostate cancer guidelines in Sweden. Scand J Urol. 2024;59:210–211. https://doi.org/10.2340/sju.v59.42656 DOI: https://doi.org/10.2340/sju.v59.42656
Stattin P. How to improve cancer care by use of guidelines and quality registers. Scand J Urol. 2024;59:190–192. https://doi.org/10.2340/sju.v59.42272 DOI: https://doi.org/10.2340/sju.v59.42272
Daskivich TJ, Chamie K, Kwan L, et al. Improved prediction of long-term, other cause mortality in men with prostate cancer. J Urol. 2011;186(5):1868–1873. https://doi.org/10.1016/j.juro.2011.07.033 DOI: https://doi.org/10.1016/j.juro.2011.07.033
Daskivich TJ, Luu M, Heard J, et al. Overtreatment of prostate cancer among men with limited longevity in the active surveillance era. JAMA Intern Med. 2025;185(1):28–36. https://doi.org/10.1001/jamainternmed.2024.5994 DOI: https://doi.org/10.1001/jamainternmed.2024.5994
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Eugenio Ventimiglia, Rolf Gedeborg, Andri Wilberg Orrason, Paolo Zaurito, Hans Garmo, Pär Stattin, Marcus Westerberg
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
